TNGX News and Press, Tango Therapeutics Inc. From 02/11/22

The following slide deck was published by Tango Therapeutics, Inc. in conjunction with this event. For further details see: Tango Therapeutics (TNGX) Investor Presentation - Slideshow

CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participa...

- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022 - Additional pipeline programs progressing throughout 2022 CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discover...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participa...

Tango Therapeutics (NASDAQ:TNGX): Q3 GAAP EPS of -$0.28. Revenue of $6.79M Press Release For further details see: Tango Therapeutics reports Q3 results

- Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 - - On track for IND filing in fourth quarter of 2021 for TNG908, an MTA- cooperative PRMT5 inhibitor that is synthetic lethal with MTAP deletion, for mult...

Tango Therapeutics (NASDAQ:TNGX) has appointed Marc Rudoltz as the company’s new Chief Medical Officer. An alumnus of the Massachusetts Institute of Technology (MIT) and SUNY-Upstate Medical University, Rudoltz has over 20 years of experience in leading clinical-stage drug develop...

Posting the third consecutive weekly loss, the healthcare stocks in the S&P 500 fell ~0.4% over the week. While healthcare became the fourth worst performing sector, the broader index edged ~0.5% higher during the week. Among healthcare stocks with more than $300M market cap and...